NCT06456125View on ClinicalTrials.gov

Safety and Efficacy Of Amber Peripheral Liquid Embolic System

NAActive, not recruitingINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

June 12, 2024

Primary Completion Date

July 31, 2026

Study Completion Date

December 31, 2026

Conditions
Vascular AnomaliesHemorrhageAneurysmPseudoaneurysmVaricose VeinsPortal Vein EmbolizationHypervascular TumorType II EndoleakPathological Organ
Interventions
DEVICE

amber SEL-P Peripheral Liquid Embolic System

Transcatheter arterial or venous embolization with the liquid embolic agent amber SEL-P embolization across seven different indications for peripheral embolization.

Trial Locations (1)

Unknown

Hospital Universitario Y Politécnico La Fe, Valencia

Sponsors

Lead Sponsor

LVD Biotech S.L
All Listed Sponsors
lead

LVD Biotech S.L

INDUSTRY

NCT06456125 - Safety and Efficacy Of Amber Peripheral Liquid Embolic System | Biotech Hunter | Biotech Hunter